AIMS/HYPOTHESIS: We compared the symptoms of hypoglycaemia induced by insulin detemir (NN304) (B29Lys(epsilon-tetradecanoyl),desB30 human insulin) and equally effective doses of neutral protamine Hagedorn (NPH) insulin in relation to possible differential effects on hepatic glucose production and peripheral glucose uptake. METHODS: After overnight intravenous infusion of soluble human insulin18 participants with type 1 diabetes receivedsubcutaneous injections of NPH insulin or insulin detemir (0.5 U/kg body weight) on separate occasions in random order. During the ensuing gradual development of hypoglycaemia cognitive function and levels of counter-regulatory hormones were measured and rates of endogenous glucose production and peripheral glucose uptake continuously evaluated using a primed constant infusion of [6,6-(2)H(2)]glucose. The study was terminated when plasma glucose concentration had fallen to 2.4 mmol/l or had reached a minimum at a higher concentration. RESULTS: During the development of hypoglycaemia no difference between the two insulin preparations was observed in symptoms or hormonal responses. Significant differences were seen in rates of glucose flux. At and below plasma glucose concentrations of 3.5 mmol/l suppression of endogenous glucose production was greater with insulin detemir than with NPH insulin, whereas stimulation of peripheral glucose uptake was greater with NPH insulin than with insulin detemir. CONCLUSIONS/ INTERPRETATION: In participants with type 1 diabetes subcutaneously injectedinsulin detemir exhibits relative hepatoselectivity compared with NPH insulin, but symptoms of hypoglycaemia and hormonal counter-regulation are similar. TRIAL REGISTRATION: ClinicalTrials.gov NCT00760448.
RCT Entities:
AIMS/HYPOTHESIS: We compared the symptoms of hypoglycaemia induced by insulin detemir (NN304) (B29Lys(epsilon-tetradecanoyl),desB30 humaninsulin) and equally effective doses of neutral protamine Hagedorn (NPH) insulin in relation to possible differential effects on hepatic glucose production and peripheral glucose uptake. METHODS: After overnight intravenous infusion of soluble humaninsulin 18 participants with type 1 diabetes received subcutaneous injections of NPH insulin or insulin detemir (0.5 U/kg body weight) on separate occasions in random order. During the ensuing gradual development of hypoglycaemia cognitive function and levels of counter-regulatory hormones were measured and rates of endogenous glucose production and peripheral glucose uptake continuously evaluated using a primed constant infusion of [6,6-(2)H(2)]glucose. The study was terminated when plasma glucose concentration had fallen to 2.4 mmol/l or had reached a minimum at a higher concentration. RESULTS: During the development of hypoglycaemia no difference between the two insulin preparations was observed in symptoms or hormonal responses. Significant differences were seen in rates of glucose flux. At and below plasma glucose concentrations of 3.5 mmol/l suppression of endogenous glucose production was greater with insulin detemir than with NPH insulin, whereas stimulation of peripheral glucose uptake was greater with NPH insulin than with insulin detemir. CONCLUSIONS/ INTERPRETATION: In participants with type 1 diabetes subcutaneously injected insulin detemir exhibits relative hepatoselectivity compared with NPH insulin, but symptoms of hypoglycaemia and hormonal counter-regulation are similar. TRIAL REGISTRATION: ClinicalTrials.gov NCT00760448.
Authors: G A Brunner; G Sendhofer; A Wutte; M Ellmerer; B Søgaard; A Siebenhofer; S Hirschberger; G J Krejs; T R Pieber Journal: Exp Clin Endocrinol Diabetes Date: 2000 Impact factor: 2.949
Authors: F Shojaee-Moradie; J K Powrie; E Sundermann; M W Spring; A Schüttler; P H Sönksen; D Brandenburg; R H Jones Journal: Diabetes Care Date: 2000-08 Impact factor: 19.112
Authors: S V M Hordern; J E Wright; A M Umpleby; F Shojaee-Moradie; J Amiss; D L Russell-Jones Journal: Diabetologia Date: 2005-02-24 Impact factor: 10.122
Authors: K Kølendorf; G P Ross; I Pavlic-Renar; G Perriello; A Philotheou; J Jendle; M-A Gall; S R Heller Journal: Diabet Med Date: 2006-07 Impact factor: 4.359
Authors: Joseph R Vasselli; F Xavier Pi-Sunyer; Daniel G Wall; Catherine S John; Colin D Chapman; Paul J Currie Journal: Am J Physiol Endocrinol Metab Date: 2017-07-18 Impact factor: 4.310
Authors: Sunil Zachariah; Ben Sheldon; Fariba Shojaee-Moradie; Nicola C Jackson; Katharine Backhouse; Sigurd Johnsen; Richard H Jones; A Margot Umpleby; David L Russell-Jones Journal: Diabetes Care Date: 2011-05-18 Impact factor: 19.112
Authors: D Russell-Jones; T Danne; K Hermansen; K Niswender; K Robertson; N Thalange; J R Vasselli; B Yildiz; H U Häring Journal: Diabetes Obes Metab Date: 2015-08-11 Impact factor: 6.577
Authors: Dale S Edgerton; Mary C Moore; Jason J Winnick; Melanie Scott; Ben Farmer; Helle Naver; Claus B Jeppesen; Peter Madsen; Thomas B Kjeldsen; Erica Nishimura; Christian L Brand; Alan D Cherrington Journal: Diabetes Date: 2014-06-19 Impact factor: 9.461